Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression

NCT02013765 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02013765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02013765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2001
Completion date
January 31, 2010
Enrollment
5 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

urinary tract cancer